Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Eur J Gastroenterol Hepatol ; 19(4): 341-6, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17353701

ABSTRACT

On the basis of limited experimental and clinical studies, increased activity of the vasodilatory nitric oxide-cyclic guanosine monophosphate pathway is considered to play a key role in the pathogenesis of hepatopulmonary syndrome. We report a 46-year-old woman with Child-Pugh class C cirrhosis and progressive dyspnoea for 12 months. Investigations revealed elevated circulating concentrations of nitric oxide metabolites and exhaled nitric oxide levels, an hyperdynamic circulation with low systemic vascular resistance and mean arterial pressure, a large right to left intrapulmonary shunt fraction on radiolabelled macroaggregated albumin perfusion scanning, positive contrast-enhanced echocardiography, reduced diffusion capacity of carbon monoxide, hypoxaemia and orthodeoxyia, all in keeping with severe hepatopulmonary syndrome. Sequential inhibition of the nitric oxide-cyclic guanosine monophosphate pathway using curcumin (diferuloylmethane), terlipressin and methylene blue was associated with substantial improvements in vascular tone and the hyperdynamic circulation. No improvement, however, in the intrapulmonary shunt was demonstrated. Both hypoxaemia and orthodeoxia were substantially, reproducibly and reversibly worsened with all three treatments. Our findings argue against the contention that intrapulmonary shunting and impairment in arterial oxygenation in hepatopulmonary syndrome are necessarily the consequence of on-going, nitric oxide-cyclic guanosine monophosphate-mediated vasodilatation, at least in the chronic stage, and, given the possibility of substantial worsening of pulmonary oxygen exchange, suggest that inhibition of the nitric oxide-cyclic guanosine monophosphate pathway should be avoided in this setting.


Subject(s)
Antihypertensive Agents/adverse effects , Curcumin/adverse effects , Cyclic GMP/antagonists & inhibitors , Hepatopulmonary Syndrome/drug therapy , Lypressin/analogs & derivatives , Nitric Oxide/antagonists & inhibitors , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Chronic Disease , Curcumin/therapeutic use , Echocardiography , Female , Hepatopulmonary Syndrome/diagnosis , Hepatopulmonary Syndrome/physiopathology , Humans , Lypressin/adverse effects , Lypressin/therapeutic use , Methylene Blue/adverse effects , Methylene Blue/therapeutic use , Middle Aged , Terlipressin , Treatment Failure , Vascular Resistance/drug effects
4.
J Am Soc Echocardiogr ; 15(9): 997-9, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12221420

ABSTRACT

We report a case of partial anomalous pulmonary venous drainage where the left upper and lower pulmonary veins drain into a separate posterior left atrial (LA) chamber before continuing as a vertical ascending vein. The vertical vein then joins the left innominate vein, which eventually drains into a normal right-sided superior vena cava. There was no fenestration or communication between this posterior chamber and the true LA. The true LA contained the fossa ovale and LA appendage. The right upper and lower pulmonary veins drain normally into the true LA. To our knowledge, this is the first case where the left upper and lower pulmonary veins drain into a separate posterior LA chamber before continuing into a vertical vein. The diagnosis was initially made with transesophageal echocardiography and confirmed by magnetic resonance imaging. The patient later underwent successful corrective operation.


Subject(s)
Pulmonary Veins/abnormalities , Adult , Diagnosis, Differential , Echocardiography, Transesophageal , Heart Defects, Congenital/diagnosis , Humans , Magnetic Resonance Imaging , Male , Pulmonary Veins/diagnostic imaging , Pulmonary Veins/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...